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Abstract
Background: Biological parameters are useful tools for understanding and monitoring complicated disease
processes. In this study, we attempted to identify proteins associated with active pulmonary tuberculosis (TB) using
a proteomic approach.
Methods: To assess TB-associated changes in the composition of human proteins, whole blood supernatants were
collected from patients with active TB and healthy control subjects. Two-dimensional difference gel electrophoresis
(2D-DIGE) was performed to analyze proteins with high molecular weights (approximately >20 kDa). Baseline
protein levels were initially compared between patients with active TB and control subjects. Possible changes of
protein patterns in active TB were also compared ex vivo between whole blood samples incubated with
Mycobacterium tuberculosis (Mtb)-specific antigens (stimulated condition) and under unstimulated conditions.
Immunoblot and enzyme-linked immunosorbent assays (ELISA) were performed to confirm differences in identified
proteins.
Results: Under the baseline condition, we found that the levels of retinol-binding protein 4 (RBP4), fetuin-A (also
called a-HS-glycoprotein), and vitamin D-binding protein differed between patients with active TB and control
subjects on 2D gels. Immunoblotting results confirmed differential expression of RBP4 and fetuin-A. ELISA results
further confirmed significantly lower levels of these two proteins in samples from patients with active TB than in
control subjects (P < 0.0001). Mtb-specific antigen stimulation ex vivo altered clusterin expression in whole blood
samples collected from patients with active TB.
Conclusions: We identified TB-associated proteins in whole blood supernatants. The dynamics of protein
expression during disease progression may improve our understanding of the pathogenesis of TB.
Background
Tuberculosis (TB) is one of the most important infec-
tious causes of death worldwide [1]. Despite its long his-
torical interaction with humans, our understanding of
host response to the TB pathogen remains incomplete.
Investigation of the molecular basis of differences in the
host immune status and metabolism between patients
with active TB and control subjects may provide a clue
to understand the disease process, and thus contribute
to future strategies for TB prevention and treatment.
Recent advances in comprehensive analytical techni-
ques, such as transcriptomics and proteomics, have
enabled us to identify proteins associated with active TB
in humans. As a pioneering approach, Jacobsen et al.
compared the gene expression profiles of peripheral
blood mononuclear cells from patients with TB and
Mtb-infected healthy donors by microarray analysis [2],
and Mistry et al. analyzed gene expression patterns in
whole blood in an attempt to find a candidate biomar-
ker for discriminating cured patients from those with a
risk of relapse [3].
Agranoff et al. [4] identified amyloid A and transthyre-
tin in human serum as potential indicators for distin-
guishing patients with TB from those with non-TB
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bination of four protein markers, including amyloid A
and transthyretin, achieved a diagnostic accuracy of up
to 78%. Chegou et al. [5] reported that EGF, VEGF,
TGF-a, and sCD40L in supernatants obtained from
interferon-gamma (IFN-g)-release assays (IGRAs) are
informative markers for differentiating active disease
from latent infection. Although the above studies are
promising, such comprehensive analytical techniques are
still in the developmental stages and further investiga-
tions are required before they can be applied clinically.
IGRA detects TB infection by measuring the Mtb-
specific immune response with high specificity [6]. IFN-g
is released by reactivation of Mtb-specific effector mem-
ory T cells in whole blood. Despite its advantages, IGRA
is not a perfect tool for use in most developing countries.
In countries with a high TB burden, patients with active
TB, and not those with latent TB infection, need to be
immediately identified and treated in order to prevent
disease transmission. However, IGRA is not capable of
distinguishing active TB from latent infection. Also, cyto-
kine measurements to be performed for IGRA are rather
expensive in a resource-limited setting and difficult to
distribute. Thus, from a practical as well as a research
standpoint, development of new markers for TB is
desired.
In the present study, by high-resolution two-dimen-
sional difference gel electrophoresis (2D-DIGE) followed
by liquid chromatography-mass spectrometry (LC-MS),
we analyzed the expression profiles of high molecular
weight proteins (approximately >20 kDa) that have not
been studied fully among components of residual whole
blood supernatants after performing IGRA.
We used two comparative frameworks. One was the
direct comparison of plasma supernatants collected
from patients with active TB and healthy control sub-
jects. This comparison aimed to identify proteins that
are markedly upregulated or downregulated in the dis-
ease state; even if such proteins are not disease specific,
they might act as useful markers for monitoring the dis-
ease before, during, and after treatment. The other com-
parative framework was more TB specific since whole
blood samples from patients were stimulated with Mtb-
specific antigens or left unstimulated, and the results
were compared.
Methods
Patients and control subjects
In this study, whole blood samples collected from
Japanese and Vietnamese individuals were used. The
study was approved by the ethical review committees of
the National Center for Global Health and Medicine
(formerly the International Medical Center of Japan),
Tokyo, Japan, and the Ministry of Health, Vietnam.
Written informed consent was obtained from each parti-
cipant. Blood samples were collected from patients with
active TB immediately before (Vietnamese patient sam-
ples) or within 7 days (Japanese patient samples) of
treatment initiation. Patients with potential complica-
tions attributable to malignancies, autoimmune diseases,
or HIV coinfection were excluded from the study.
At the initial screening and confirmation stage, blood
samples were collected from 14 Japanese patients with
bacteriologically confirmed active pulmonary TB (9 men
and 5 women; median age 50 years, range 22-75 years)
and 13 age- and gender-matched healthy Japanese
patients (8 men and 5 women; median age 48 years,
range 24-64 years). We could not completely rule out
the possibility of latent TB infection in 2 of the 13 con-
trol subjects, according to the results of a commercially
available IGRA (QuantiFERON
®-TB Gold in Tube; Cel-
lestis, Victoria, Australia). However, we analyzed all
samples together at the initial stage to identify proteins
associated with active TB disease. The tuberculin skin
test was not useful for detecting latent TB infection in
our study since most individuals in the tested popula-
tions had received BCG vaccination after birth. Blood
samples from 4 patients with active TB and 4 healthy
individuals were chosen for screening by 2D-DIGE and
immunoblotting. The stability of proteins measured by
the enzyme-linked immunosorbent assay (ELISA) was
investigated by comparing a set of plasma samples
directly separated from EDTA-containing peripheral
blood and another set of plasma supernatants obtained
from heparinized blood after 18 h of incubation (under
the same conditions as the IGRA negative control).
At the next verification stage, we utilized samples
from 25 Vietnamese patients with sputum smear-
positive active pulmonary TB (13 men and 12 women;
median age 35 years, range 20-55 years) and 50 age- and
gender-matched Vietnamese healthy control subjects
(26 men and 24 women; median age 36 years, range
21-54 years) of which 25 were IGRA positive and 25 were
IGRA negative. None of the IGRA-positive individuals
had any signs or symptoms of active TB but at least some
were reasonably suspected to have latent TB infections
because the prevalence of TB in the population is high.
Following IGRA, the remaining unstimulated plasma
supernatants were used for ELISA.
Sample collection and preparation
Whole blood was separately collected in heparin-
containing tubes precoated with mitogen as a positive
control or cocktails of ESAT-6, CFP-10, and TB7.7 (p4)
peptides as Mtb-specific antigens (QuantiFERON
®-TB
Gold in Tube; Cellestis); the negative control tubes had
no precoat. After 18 h of incubation at 37°C, each sam-
ple was centrifuged and the plasma supernatants were
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assays. For proteomic analysis, four sample sets that
were either unstimulated or stimulated with Mtb-
specific antigens or mitogen from patients with active
pulmonary TB and four corresponding sets from control
subjects were used to screen for candidate proteins by
2D-DIGE. To increase resolution, 14 human major
plasma proteins (albumin, IgG, antitrypsin, IgA, transfer-
rin, haptoglobin, fibrinogen, alpha 2-macroglobulin,
alpha 1-acid glycoprotein, IgM, apolipoprotein Al, apoli-
poprotein All, complement C3, and transthyretin) were
removed prior to electrophoresis using a Multiple Affi-
nity Removal LC Column-Human 14 (Agilent Technolo-
gies, Santa Clara, CA, USA). The samples were then
concentrated by ultrafiltration (Agilent Technologies,
Concentrators Spin 5 kDa MWCO, 4 ml) followed by
acetone precipitation in preparation for subsequent
electrophoresis.
Quantitative analyses by 2D-DIGE
Protein samples were labeled with Cy3 and Cy5 (DIGE
Fluors Minimal Labeling Dyes; GE Healthcare, Buckin-
ghamshire, UK) according to the manufacturer’s instruc-
tions. The samples (50 μg of total protein per gel) were
applied to Immobiline DryStrips (18 cm long, pH 4-7
linear; Amersham Biosciences, Pittsburgh, PA, USA),
and isoelectric focusing (IEF) was performed using an
Ettan IPGphor IEF system (Amersham Biosciences)
according to the manufacturer’s instructions. Next, SDS-
PAGE was performed using a 10-18% linear gradient gel
from DRC Co., Ltd. (Tokyo, Japan). The fluorescence
intensity of each protein spot was digitally recorded
using a Molecular Imager FX system (Bio-Rad Labora-
tories, Hercules, CA, USA) with Quantity One software
(Bio-Rad Laboratories), and differential protein expres-
sion was quantitatively analyzed using the PDQuest soft-
ware (Bio-Rad Laboratories). The same gel included a
reference sample that had been labeled with Cy2 and
was used for spot matching, image analysis, and volume
normalization. Initially, all spots were roughly matched
using an automated tool in the PDQuest software suite.
This estimate was followed by a more detailed manual
curation to correct any inappropriately matched pairs of
protein spots.
Sample preparation for mass spectrometry
A mixture of all samples (400 μg of total protein per
gel) was subjected to 2D-DIGE under the same condi-
tions as described above to isolate selected spots. To
visualize individual protein spots, the gels were stained
with SYPRO Ruby protein gel stain (Molecular Probes,
Eugene, OR, USA) for 3 h. The fluorescence intensity of
each protein spot was digitally measured using the
Molecular Imager FX system with Quantity One soft-
ware. Mass spectrometric analysis was performed
according to the method reported by Toda et al. [7],
with slight modification. Briefly, each protein spot on
SYPRO Ruby stained gels was picked using a spot picker
(Amersham Biosciences). In-gel digestion of proteins
was performed according to the method reported by
Saeki et al. [8].
Mass spectrometric analysis
An ESI ion-trap mass spectrometer (LCQ Deca XP Plus,
Thermo Electron) was used for peptide detection. Mass
spectrometric analysis was performed as described pre-
viously [8]. Protein identification was performed using
the Mascot server (Matrix Science, Boston, MA, USA)
and Protein Prospector (UCSF Mass Spectrometry Facil-
ity, San Francisco, CA, USA). We selected the SWISS-
PROT Homo sapiens database and used the following
parameters: peptide tolerance 1.0 Da and one missed
cleavage. Carbamidomethyl modification of cysteine,
acetylation of the NH2-terminal ends of lysine, and
phosphorylation of serine, threonine, or tyrosine were
considered in this analysis.
Immunoblotting
Immunoblotting to detect the proteins identified as
described above was performed using anti-human
retinol-binding protein 4 (RBP4) rabbit polyclonal IgG
(A-0040; Dako; Glostrup, Denmark), anti-human fetuin-
A( A H S G )g o a tp o l y c l o n a lI g G( G - 2 0 ;S a n t aC r u z
Biotechnology; Santa Cruz, CA, USA), anti-human vita-
min D-binding protein (VDBP) (Gc-Globulin) rabbit
polyclonal IgG (Dako), anti-human clusterin-a mouse
monoclonal IgG1 (B-5; Santa Cruz Biotechnology), or
anti-human clusterin-b rabbit polyclonal IgG (N-18;
Santa Cruz Biotechnology).
Total protein concentrations were determined using
the Bio-Rad protein assay kit (Bio-Rad Laboratories). To
detect clusterin-a and -b, mixed protein samples
(20 μg )w e r ea p p l i e dt o2 DP A G Ew i t h1 DI E Fu s i n g
the Immobiline DryStrip (pH 3-5.6 nonlinear). Proteins
were then transferred to PVDF membranes. The
membranes were probed with polyclonal antibodies,
anti-clusterin-a,a n da n t i - c l u s t e r i n - b. To detect other
proteins, each sample (10 μg) was subjected to conven-
tional SDS-PAGE. Membranes were probed with anti-
VDBP, anti-fetuin-A, or anti-RBP4 polyclonal antibodies.
Anti-mouse and anti-rabbit (GE Healthcare) as well as
anti-goat (Santa Cruz Biotechnology) HRP-conjugated
secondary antibodies were prepared. Protein bands were
detected using the ECL plus detection reagent (GE
Healthcare). Band intensities were calculated using the
Quantity One software.
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A competitive ELISA for quantitative determination of
RBP4 in human plasma was performed according to the
manufacturer’s instructions (AdipoGen Inc.; Seoul,
Korea). The detection limit was 1 ng/ml. An AHSG
ELISA kit was used to detect fetuin-A in plasma (Bio-
Vender Laboratory Medicine Inc.; Modrice, Czech
Republic). The detection limit was 0.35 ng/ml. A Quan-
tikine
® Human Vitamin D-Binding Protein Immunoas-
say kit was used to detect VDBP in plasma (R&D
Systems, Inc.; Minneapolis, MN, USA). The mean mini-
mum detectable VDBP level was 0.65 ng/ml. Distribu-
tion of levels was represented using the median and
interquartile range (IQR).
Statistical analysis
Proteins showing differential expression between two
conditions were first determined with P values using the
Student’s t-test preinstalled in the PDQuest software
suite. To select candidate proteins with expression levels
that differed between unstimulated samples from
patients with active TB and healthy control subjects, a
significance level of P < 0.05 was selected. To select can-
didate proteins showing differential expression in Mtb-
specific antigen-stimulated and unstimulated plasma
samples, a less stringent cut-off value of P <0 . 1 0w a s
applied. Assuming an alpha error of 0.1 and a standar-
dized effect size of 2.0, the power to detect a difference
was calculated as 0.8 given our sample size. When a
normal distribution of measurements was not predicted,
the Wilcoxon rank sum test (Mann-Whitney U test)
was applied for confirmation using the JMP software
(version 7.0.1; SAS Institute, Cary, NC, USA).
Results
Quantitative analyses by 2D-DIGE
In a preliminary experiment, we used an immobilized
linear pH gel strip with a broad pH range (pH 3-10 lin-
e a r )f o r1 DI E F .A l t h o u g hm o r et h a n5 0 0p r o t e i ns p o t s
were visualized in fresh plasma with SYPRO Ruby stain-
ing, the number of spots after incubation of whole
blood with stimuli decreased, and detectable spots were
primarily located in the pH range 4-7 (data not shown).
Therefore, we performed subsequent analyses using an
i m m o b i l i z e dl i n e a rp Hg e ls t r i pw i t han a r r o w e rr a n g e
(pH 4-7 linear) to obtain a finer resolution. We used
two comparative frameworks in our analyses, and the
corresponding spot patterns are schematically depicted
in Figure 1.
Differential gel images were acquired and displayed
using the PDQuest 2D gel analysis software (Figure 2A,
B). In our comparison of the protein expression profiles
of patients with active TB and control subjects, red indi-
cates proteins increased in the supernatants collected
from the patients and green indicates proteins decreased
in the patients compared with the control subjects.
Yellow indicates no significant differences (Figure 2A).
In 2D gel profiles comparing the antigen-stimulated and
unstimulated samples collected from patients with active
TB, red indicates proteins increased in the supernatants
after Mtb-specific antigen stimulation, and green indi-
cates proteins decreased after stimulation. Yellow indi-
cates no significant changes (Figure 2B). From 367 spots
compared between patients with active TB and control
subjects, and 293 spots generated with samples collected
from patients with active TB that were either stimulated
with Mtb-specific antigens or left unstimulated, we
selected several candidates for subsequent mass spectro-
metric analysis (Table 1) according to the criteria
described in the Materials and Methods section.
Mass spectrometric analysis
Following the above criteria for selecting candidates of
differentially expressed proteins between two conditions,
a total of 41 spots were isolated from the corresponding
2D gels on the basis that they showed sufficiently strong
Figure 1 Schematic representation of protein expression
profiles. Comparison between subjects, in particular, spot patterns
showing differences in plasma proteomes between patients and
control subjects. Comparison between the presence and absence of
stimuli, especially ex vivo spot patterns of Mtb-specific antigen-
stimulated plasma samples and unstimulated samples from patients.
Two major comparative frameworks in our study are shown (bold
arrows).
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followed by LC-MS analysis. The proteins corresponding
to 14 of these spots were successfully identified
(Figure 3).
Of the 14 proteins in Table 2, 7 (serial numbers 1 to
7) were obtained as a result of comparisons between
patients with active TB and control subjects; number 1
(spot HT6102) was identified as RBP4, number 2
(HT2406) as fetuin-A, and number 3 (HT5401) as
VDBP. Four (numbers 8 to 11) were obtained as a result
of comparisons between nonspecific mitogen-stimulated
and unstimulated samples collected from patients with
active TB (not analyzed in this study). The last 3 pro-
teins (numbers 12 to 14) were obtained as a result of
comparisons between Mtb-specific antigen-stimulated
and unstimulated samples collected from patients with
active TB; numbers 12 to 14 (T4203, T3107, and
T4208) were all identified as clusterin. In Table 2, P
values indicating a significant difference between the
means of the two conditions examined, the SWISS-
PROT accession numbers of the identified proteins as
well as their molecular weights and theoretical pI values
are indicated. We also used the Homo sapiens database
of expressed sequence tags (ESTs) to identify clusterin
in spot T4208.
Mascot search scores (indices of protein matches)
were 47, 50, 98, 75, and 72 for spots T4203 (clusterin),
T3107(clusterin), HT5401 (VDBP), HT2406 (fetuin-A),
and HT6102 (RBP4), respectively, (Table 2), suggesting
that identification of these proteins using peak lists of
MS/MS spectra obtained from the LC-MS/MS system
are fairly reliable since all these scores were significant
Figure 2 2D-DIGE-based protein expression analysis. Pseudo-colored images were generated using the Multi-Channel Viewer function of the
PDQuest software suite. Four sample sets that were either unstimulated or stimulated with the Mtb-specific antigen or mitogen from patients
with active pulmonary TB and four corresponding sets from control subjects were used to screen for candidate proteins by 2D-DIGE. A: Analysis
based on differences in levels in samples from patients and control subjects. Red indicates proteins whose levels increased and green indicates
proteins whose levels decreased in unstimulated supernatants from patients with active TB compared with control subjects. Spot (a): HT6102,
Spot (b): HT2406, and Spot (c): HT5401 correspond to the PDQuest identification numbers shown in Table 2. B: Analysis based on differences in
levels after stimulation. Red indicates proteins whose levels increased in whole blood supernatants from patients with active TB after incubation
with Mtb-specific antigens. Spots (d): T3107, T4203, and T4208, correspond to Table 2.
Table 1 The number of spots that may show differential expression
A: Comparison between patients with active TB and control subjects
P < 0.02 0.02≤P < 0.05 0.05≤P < 0.10
Patients versus control subjects 18 12 24
B: Comparison between stimulated and unstimulated conditions
P < 0.02 0.02≤P < 0.05 0.05≤P < 0.10
Patients Mtb antigens versus no stimuli 0 2 2
Mitogen versus no stimuli 3 5 11
Control subjects Mtb antigens versus no stimuli 0 1 13
Mitogen versus no stimuli 2 83 8
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teins with comparable scores were detected for each gel
spot (See Additional file 1: for supporting information).
These proteins were interesting because of their poten-
tial biological significance,a n dw et h e r e f o r ea n a l y z e d
them further.
Confirmation of differentially expressed proteins by
immunoblotting
Immunoblot analysis was used to confirm differential
expression of three proteins identified in patients with
active TB compared with control subjects (Figure 4A).
We measured band densities using the same samples
prepared for protein confirmation (Figure 4B). The band
density of RBP4 in patients with active TB (64,283 arbi-
trary units ± 3,861) was lower than that in control sub-
jects (445,894 ± 16,590), and fetuin-A expression in the
patients was also lower (42,710 ± 7,580) than that in
control subjects (343,617 ± 58,923). These results are
consistent with those of 2D gel analysis. Moreover, the
band density of VDBP tended to be higher in samples
from patients with active TB than from control subjects,
which is similar to that observed above; however, the
protein levels were widely distributed and the differ-
ences in these levels did not reach significance in the
control subjects compared with patients with active TB
(33,251 ± 2,572 versus 38,971 ± 11,001). Because the
three clusterin spots altered after Mtb-specific antigen
stimulation were not clearly distinguished by immuno-
blotting, we did not attempt any further demonstration
of changes in these signals in our study. Instead, pooled
samples were run on a 2D gel and followed by immuno-
blotting with anti-clusterin-a and anti-clusterin-b anti-
bodies (because clusterin consists of clusterin-a and -b
subunits) (Figure 4C). Based on immunoreactivity and
pI values, the spots detected were confirmed to be
clusterin-a. More specifically, the three spots comprised
a subset of possible modified forms of clusterin-a that
may be detected.
Detection of differentially expressed proteins by ELISA
Because RBP4 and fetuin-A levels determined by immu-
noblotting were significantly different between samples
from patients with active TB and control subjects, we
performed further quantitative ELISA to extend the
measurements to plasma samples from 14 Japanese
patients with active TB and 13 age-, gender-, and ethni-
city-matched control subjects. Plasma RBP4 levels in
patients with active TB (median = 23.6 μg/ml; IQR =
18.4-37.9) were significantly lower than those from con-
trol subjects (median = 44.6 μg/ml; IQR = 34.6-53.8; P =
0.0033; Figure 5A). Plasma fetuin-A levels in patients
(median = 147.9 μg/ml; IQR = 115.8-159.6) were
also significantly lower than those in control subjects
(median = 211.0 μg/ml; IQR = 186.7-264.6; P = 0.0002;
Figure 5B). No significant difference were observed
in plasma VDBP levels between patients (median =
110.0 μg/ml; IQR = 85.2-151.3) and control subjects
(median = 105.0 μg/ml; IQR = 88.1-215.6; P = 0.5441;
Figure not shown).
We simultaneously compared the protein levels in
plasma immediately separated from EDTA-containing
blood with those in plasma supernatants obtained from
heparinized blood as a negative control for IGRA after
18 h of incubation without stimulants. We found that
the differences between the two types of plasma samples
were small (coefficient of variance (CV) = 10.5% for
RBP4; CV = 5.0% for fetuin-A; CV = 6.6% for VDBP)
and was in a range of variation generally accepted in
ELISA (CV < 15%), indicating that the measurements
obtained under the latter condition can be substituted
for those obtained under the former condition. Indeed,
plasma RBP4 and fetuin-A levels in samples from
Japanese patients with active TB were significantly lower
than those from control subjects, irrespective of plasma
conditions (data not shown).
Figure 3 Representative 2D gel image obtained from pooled
protein samples. Differentially expressed proteins successfully
identified by LC-MS were represented on the gel using the PDQuest
software suite. See Table 2 for additional information. Numbers in
the figure correspond to serial numbers in Table 2.
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with samples from a different ethnic and regional popula-
tion, i.e., samples collected from Vietnamese patients.
The two proteins identified above were measured in
plasma supernatants from Vietnamese patients with
active TB and age-, gender-, and ethnicity-matched con-
trol subjects. The samples from these Vietnamese
patients were obtained from a negative control of IGRA
after incubation without stimulants. RBP4 levels in
patients with active TB (median = 17.5 μg/ml; IQR =
14.4-23.9) were significantly lower than those in control
subjects (median = 30.5 μg/ml; IQR = 25.9-40.8; P <
0.0001; Figure 5A). Fetuin-A levels in patients with active
TB (median = 210.7 μg/ml; IQR = 178.1-235.7) were also
significantly lower than those in control subjects (median =
299.4 μg/ml; IQR = 265.1-363.2; P < 0.0001; Figure 5B).
Moreover, both protein levels were not significantly differ-
ent between IGRA-negative and IGRA-positive subgroups
of the control subjects (data not shown).
Discussion
In this study, we identified TB-associated proteins from
whole blood supernatants. After the removal of 14
major plasma proteins, RBP4, fetuin-A, and VDBP were
initially identified as plasma proteins from unstimulated
samples for which the baseline levels differed between
the patients and control subjects. Immunoblotting
results confirmed the differential expression of RBP4
and fetuin-A between the two groups. Although VDBP
has previously been identified as a biomarker for myco-
bacterial infections in cattle [9], the level of this protein
did not differ significantly in our study because of large
individual variations. The changes in VDBP levels may
not have been accurately immunologically assayed in
our study.
Clusterin is a secreted glycoprotein involved in apop-
tosis, inflammation, and tissue injury. It was differen-
tially expressed in patients with active TB after
stimulation and the intensities of the three spots
Table 2 Characteristics of proteins identified in this study
A: Comparison between patients with active TB and control subjects
2D-DIGE LC-MS/MS
Condition Serial
Number
PDQ
SSP#
a
P
value
+/-
b Swiss-Plot Mascot search
score
e
Protein name Da pI
Patients versus control
subjects
1 HT6102 0.0064 - RET4_HUMAN 72 Retinol binding
protein 4
23010 5.76
2 HT2406 0.0097 - FETUA_HUMAN 75 a-2-HS-glycoprotein 39325 5.43
3 HT5401 0.0331 + VTDB_HUMAN 98 Vitamin D binding
protein
52964 5.40
4 HT2303 0.0419 + CO4A_HUMAN 86 Complement C4A 192771 6.66
5 HT1012 0.0271 - APOC3_HUMAN 105 Apolipoprotein C-III 10852 5.23
6 HT5303 < 0.001 - APOA4_HUMAN 190 Apolipoprotein A-IV 45399 5.28
7 HT1016 0.0024 - APOC2_HUMAN 61 Apolipoprotein C-II 11284 4.72
B: Comparison between stimulated and unstimulated conditions in active TB
2D-DIGE LC-MS/MS
Condition Serial
Number
PDQ
SSP#
P
value
+/-
c Swiss-Plot Mascot search
score
Protein name Da pI
Mitogen (versus no stimuli) 8 T3601 0.0917 - C1S_HUMAN 169 Complement-C1S 76684 4.86
9 T3403 0.0156 + KNG1_HUMAN 139 Kininogen-1 71957 6.34
10 T3105 0.0866 - ZA2G_HUMAN 45 Zinc-a-2-glycoprotein 33872 5.57
11 T4512 0.0061 - A1BG_HUMAN 76 a-1B-glycoprotein 54273 5.58
Mtb antigens (versus no
stimuli)
12 T4203 0.0640
d + CLUS_HUMAN 47 Clusterin 52495 5.89
13 T3107 0.0687
d + CLUS_HUMAN 50 Clusterin 52495 5.89
14 T4208 0.0732
d + EST – Clusterin 52495 5.89
aPDQ SSP# is a PDQuest software standard spot number indicating the unique location of each spot automatically assigned on a 2D gel and is essential for
comparing the same spots on different gels.
bThe average density of a spot from 2D-DIGE is higher (+) or lower (-) in patients with active TB than in control subjects.
cThe average density of the spot from 2D-DIGE is higher (+) or lower (-)under the stimulated condition than that under the unstimulated condition.
dThe average density of the 3 spots, T4203, T3107, and T4208, which correspond to a subset of clusterin, was significantly higher in Mtb-specific antigen-
stimulated than in unstimulated samples (P = 0.0014).
eThe Mascot search score indicates the degree of compatibility between mass spectra generated by the sample and amino acid sequences within the proteino f
interest.
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blood supernatant samples after incubation with Mtb-
specific antigens. These spots appear to have shifted in
both the dimensions on the gel, which suggests small
changes in their molecular weights and IEPs. It is con-
ceivable that post-translational modifications, such as
degradation and/or deglycosylation, occur via an enzy-
matic reaction that accompanies immune cell activation.
H o w e v e r ,w eh a v en o td e m o n s t r a t e dt h a tt h i sr e s p o n s e
is observed only when Mtb-specific antigens are co-
incubated. To determine whether clusterin has a role as
a marker of TB or indicates more general response to
antigen stimulation, we are currently attempting to find
clear and simple methods in detecting these alterations
for mass screening.
Subsequent ELISA results for samples from Japanese
and Vietnamese subjects confirmed that both plasma
RBP4 and fetuin-A levels were significantly lower in
samples collected from patients with active TB than in
control subjects, indicating that our findings are repro-
ducible in studies using well-matched control subjects.
However, as shown in Figure 5, the average plasma
levels of these proteins differed between Japanese and
Vietnamese control subjects. This suggests that
unknown factors may systemically influence tested
populations or the measurement of these markers.
Because this variance is crucial in a clinical setting,
further basic as well as clinical investigations are neces-
sary to accurately assess these markers.
No significant differences were observed in RBP4 and
fetuin-A levels in samples from IGRA-positive and
-negative control subjects. This suggests that these pro-
teins levels are not affected by latent TB infection, but
that they presumably change during disease progression
via an unknown mechanism.
Intriguingly, the literature supports the idea that RBP4
and fetuin-A are functionally significant since they may
be involved in macrophage activation [10-12]. Retinoic
acid has been shown to stimulate and induce monocyte
differentiation, leading to inhibition of Mtb multiplica-
tion in human macrophages [13]. RBP4 is the specific
carrier protein for retinol (vitamin A) and has recently
been described as an adipokine that contributes to insu-
lin resistance [13]. This protein is believed to modulate
pathophysiological processes during bacterial infection.
Fetuin-A was originally identified as a fetal protein and
has been shown to affect the development of many
mammalian tissues. Moreover, the results of in situ
mRNA hybridization and immunocytochemical studies
in adult sheep have revealed that the main sites of
fetuin-A expression are hepatocytes and monocytes or
macrophages in the spleen and bone marrow [14].
Fetuin-A is known to modulate various immune and
metabolic responses. Previous reports have shown that
fetuin-A deactivates macrophages, acts as an opsonin
for cationic-deactivating molecules including spermine
[15], reduces TNF-a production and inflammatory
responses [16], and enhances phagocytosis of apoptotic
cells and macropinocytosis by human macrophages [17].
On the other hand, this protein is known to be a potent
inhibitor of systemic calcification [18] and is associated
with the incidence of diabetes mellitus [19].
Our study is the first to highlight the relationship
between these two markers and TB, even though these
marker levels may be affected by endogenous or exogen-
ous factors and are presumably nonspecific to TB given
their relative abundance in plasma and the broad spec-
trum of functional significance proposed in the above
references.
Nevertheless, performing a prospective cohort study
m a yh e l pc l a r i f yt h er o l eo ft h e s ep r o t e i n si nT B .
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Figure 4 Comparison of candidate differential proteins using
immunoblotting. Samples were first treated to remove 14 major
proteins and then analyzed by immunoblotting to facilitate
comparison of RBP4, fetuin-A, and VDBP levels. (A) Representative
immunoblot of samples from patient with active TB (Patient-1)
versus a control subject (Control-1). (B) Band densities were
quantified in patients (n = 4) and control subjects (n = 4). The PMT
response suggested band densities. (C) Two-dimensional
immunoblot of pooled samples with detection of clusterin-a and
-b. CLU is clusterin.
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Page 8 of 10If within-individual variation in baseline levels is rela-
tively small, it can be used to monitor the course of dis-
ease before, during, and after treatment. Further clinical
studies on various conditions may better characterize
these proteins. Single use of these markers or their com-
bined use with other promising biomarkers may be a
useful tool to aid the development of new effective
therapies and vaccines.
Conclusions
We identified three TB-associated proteins, RBP4,
fetuin-A, and clusterin, in whole blood supernatants
using a proteomic approach. We subsequently showed
that both plasma RBP4 and fetuin-A levels are signifi-
cantly and reproducibly lower in patients with active TB
than in control subjects. These findings may help us
understand and monitor the disease process in TB.
Additional material
Additional file 1: Figure S1 - Mascot search results–Information
about the identified proteins obtained using the Mascot server. (A)
Mascot search result for T2116 (clusterin) (B) Mascot Search Result for
T2103 (clusterin) EST (C) Mascot search result for T1486 (clusterin) (D)
Mascot search result for HT2482 (RET4 = RBP4) (E) Mascot search result
for HT1248 (fetuin-A) (F) Mascot search result for HT1240 (VDBP).
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